Review



u133a plus 2 0 dna microarray  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Thermo Fisher u133a plus 2 0 dna microarray
    Overview of IRSN-23 pCR-prediction without anti-HER2 therapy in breast cancer. A Meta-analysis of all datasets. The gray-shaded areas show the results of the present study. B Pooled analysis of each subtype and treatment. C IRSN-23 immune scores (IS) and pCR rates for each subtype. The solid lines and bands represent loess regression fitting (span = 2), and 95% confidence intervals were implemented using the R function geom_smooth. Abbreviations in the figure are as follows: GPL570 Affymetrix Human Genome U133 Plus 2.0 Array, GPL571 Affymetrix Human Genome <t>U133A</t> 2.0 Array, GPL96 Affymetrix Human Genome U133A Array, GPL6884 Illumina HumanWG-6 v3.0 expression beadchip, GPL1352 Affymetrix Human X3P, GPL6480 Agilent-014850 Whole Human Genome Microarray 4 × 44 K G4112F, A anthracycline, T taxane, Pac paclitaxel, Doc docetaxel, Ixa ixabepilone. Predictors of chemotherapy sensitivity and clinical utility
    U133a Plus 2 0 Dna Microarray, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/u133a plus 2 0 dna microarray/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    u133a plus 2 0 dna microarray - by Bioz Stars, 2026-04
    99/100 stars

    Images

    1) Product Images from "IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses"

    Article Title: IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses

    Journal: Breast Cancer (Tokyo, Japan)

    doi: 10.1007/s12282-025-01687-6

    Overview of IRSN-23 pCR-prediction without anti-HER2 therapy in breast cancer. A Meta-analysis of all datasets. The gray-shaded areas show the results of the present study. B Pooled analysis of each subtype and treatment. C IRSN-23 immune scores (IS) and pCR rates for each subtype. The solid lines and bands represent loess regression fitting (span = 2), and 95% confidence intervals were implemented using the R function geom_smooth. Abbreviations in the figure are as follows: GPL570 Affymetrix Human Genome U133 Plus 2.0 Array, GPL571 Affymetrix Human Genome U133A 2.0 Array, GPL96 Affymetrix Human Genome U133A Array, GPL6884 Illumina HumanWG-6 v3.0 expression beadchip, GPL1352 Affymetrix Human X3P, GPL6480 Agilent-014850 Whole Human Genome Microarray 4 × 44 K G4112F, A anthracycline, T taxane, Pac paclitaxel, Doc docetaxel, Ixa ixabepilone. Predictors of chemotherapy sensitivity and clinical utility
    Figure Legend Snippet: Overview of IRSN-23 pCR-prediction without anti-HER2 therapy in breast cancer. A Meta-analysis of all datasets. The gray-shaded areas show the results of the present study. B Pooled analysis of each subtype and treatment. C IRSN-23 immune scores (IS) and pCR rates for each subtype. The solid lines and bands represent loess regression fitting (span = 2), and 95% confidence intervals were implemented using the R function geom_smooth. Abbreviations in the figure are as follows: GPL570 Affymetrix Human Genome U133 Plus 2.0 Array, GPL571 Affymetrix Human Genome U133A 2.0 Array, GPL96 Affymetrix Human Genome U133A Array, GPL6884 Illumina HumanWG-6 v3.0 expression beadchip, GPL1352 Affymetrix Human X3P, GPL6480 Agilent-014850 Whole Human Genome Microarray 4 × 44 K G4112F, A anthracycline, T taxane, Pac paclitaxel, Doc docetaxel, Ixa ixabepilone. Predictors of chemotherapy sensitivity and clinical utility

    Techniques Used: Expressing, Microarray



    Similar Products

    u133a plus 2 0 dna microarray  (Thermo Fisher)
    99
    Thermo Fisher u133a plus 2 0 dna microarray
    Overview of IRSN-23 pCR-prediction without anti-HER2 therapy in breast cancer. A Meta-analysis of all datasets. The gray-shaded areas show the results of the present study. B Pooled analysis of each subtype and treatment. C IRSN-23 immune scores (IS) and pCR rates for each subtype. The solid lines and bands represent loess regression fitting (span = 2), and 95% confidence intervals were implemented using the R function geom_smooth. Abbreviations in the figure are as follows: GPL570 Affymetrix Human Genome U133 Plus 2.0 Array, GPL571 Affymetrix Human Genome <t>U133A</t> 2.0 Array, GPL96 Affymetrix Human Genome U133A Array, GPL6884 Illumina HumanWG-6 v3.0 expression beadchip, GPL1352 Affymetrix Human X3P, GPL6480 Agilent-014850 Whole Human Genome Microarray 4 × 44 K G4112F, A anthracycline, T taxane, Pac paclitaxel, Doc docetaxel, Ixa ixabepilone. Predictors of chemotherapy sensitivity and clinical utility
    U133a Plus 2 0 Dna Microarray, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/u133a plus 2 0 dna microarray/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    u133a plus 2 0 dna microarray - by Bioz Stars, 2026-04
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Overview of IRSN-23 pCR-prediction without anti-HER2 therapy in breast cancer. A Meta-analysis of all datasets. The gray-shaded areas show the results of the present study. B Pooled analysis of each subtype and treatment. C IRSN-23 immune scores (IS) and pCR rates for each subtype. The solid lines and bands represent loess regression fitting (span = 2), and 95% confidence intervals were implemented using the R function geom_smooth. Abbreviations in the figure are as follows: GPL570 Affymetrix Human Genome U133 Plus 2.0 Array, GPL571 Affymetrix Human Genome U133A 2.0 Array, GPL96 Affymetrix Human Genome U133A Array, GPL6884 Illumina HumanWG-6 v3.0 expression beadchip, GPL1352 Affymetrix Human X3P, GPL6480 Agilent-014850 Whole Human Genome Microarray 4 × 44 K G4112F, A anthracycline, T taxane, Pac paclitaxel, Doc docetaxel, Ixa ixabepilone. Predictors of chemotherapy sensitivity and clinical utility

    Journal: Breast Cancer (Tokyo, Japan)

    Article Title: IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses

    doi: 10.1007/s12282-025-01687-6

    Figure Lengend Snippet: Overview of IRSN-23 pCR-prediction without anti-HER2 therapy in breast cancer. A Meta-analysis of all datasets. The gray-shaded areas show the results of the present study. B Pooled analysis of each subtype and treatment. C IRSN-23 immune scores (IS) and pCR rates for each subtype. The solid lines and bands represent loess regression fitting (span = 2), and 95% confidence intervals were implemented using the R function geom_smooth. Abbreviations in the figure are as follows: GPL570 Affymetrix Human Genome U133 Plus 2.0 Array, GPL571 Affymetrix Human Genome U133A 2.0 Array, GPL96 Affymetrix Human Genome U133A Array, GPL6884 Illumina HumanWG-6 v3.0 expression beadchip, GPL1352 Affymetrix Human X3P, GPL6480 Agilent-014850 Whole Human Genome Microarray 4 × 44 K G4112F, A anthracycline, T taxane, Pac paclitaxel, Doc docetaxel, Ixa ixabepilone. Predictors of chemotherapy sensitivity and clinical utility

    Article Snippet: Gene expression analysis was performed using Affymetrix U133A Plus 2.0 DNA microarray since the last publication.

    Techniques: Expressing, Microarray